Incretin Receptors in Non-Neoplastic and Neoplastic Thyroid C Cells in Rodents and Humans: Relevance for Incretin-Based Diabetes Therapy
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
While incretins are of great interest for the therapy of diabetes 2, the focus has recently been brought to the thyroid, since rodents treated with glucagon-like peptide-1 (GLP-1) analogs were found to occasionally develop medullary thyroid carcinomas. Incretin receptors for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) were therefore measured in various rodent and human thyroid conditions. In vitroGLP-1 and GIP receptor autoradiography were performed in normal thyroids, C-cell hyperplasia and medullary thyroid carcinomas in rodents. Receptor incidence and density were assessed and compared with the receptor expression in human thyroids, medullary thyroid carcinomas, and TT cells. GLP-1 receptors are expressed in C cells of normal rat and mice thyroids. Their density is markedly increased in rat C-cell hyperplasia and medullary thyroid carcinomas, where their incidence amounts to 100%. GIP receptors are neither detected in normal rodent thyroids nor in C-cell hyperplasia, but are present in all rat medullary thyroid carcinomas. No GLP-1 or GIP receptors are detected in normal human thyroids. Whereas only 27% of all human medullary thyroid carcinomas express GLP-1 receptors, up to 89% express GIP receptors in a high density. TT cells lack GLP-1 receptors but express GIP receptors. GLP-1 receptors are frequently expressed in non-neoplastic and neoplastic C cells in rodents while they are rarely detected in human C-cell neoplasia, suggesting species differences. Conversely, GIP receptors appear to be massively overexpressed in neoplastic C cells in both species. The presence of incretin receptors in thyroid C cell lesions suggests that this organ should be monitored before and during incretin-based therapy of diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Healthy human thyroid C cells do not express GLP 1 receptors”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [56]
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 1×
“During preclinical development, it was observed in animal studies evaluating the long-term effect of GLP-1 analogs that a significant number of animals developed medullary thyroid carcinomas [”
BackgroundGerm-line mutations in p27 Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans
Pellegata, N. S., Quintanilla-Martinez, L., Siggelkow, H., Samson, E., Bink, K., Höfler, H., Fend, F., Graw, J., & Atkinson, M. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603877103 · Cited by 644
Self-citationThe incretin system and its role in type 2 diabetes mellitus
HOLST, J., VILSBOLL, T., & DEACON, C. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 515
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 1×
“This observation is puzzling. In a study on GLP-1 receptors in cancer tissue [”
Self-citationIslet G protein-coupled receptors as potential targets for treatment of type 2 diabetes
Ahrén, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2782 · Cited by 419
Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan
Wang, L.-Y., Hatch, M., Chen, C.-J., Levin, B., You, S.-L., Lu, S.-N., Wu, M.-H., Wu, W.-P., Wang, L.-W., Wang, Q., et al. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960904)67:5<620::aid-ijc5>3.0.co;2-w · Cited by 259
Self-citationEhses, J. A., Casilla, V. R., Doty, T., Pospisilik, J. A., Winter, K. D., Demuth, H.-U., Pederson, R. A., & McIntosh, C. H. S. (2003) · Endocrinology · doi:10.1210/en.2002-0068 · Cited by 159
Kim, S., Nian, C., Widenmaier, S. B., & McIntosh, C. H. S. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00325-07 · Cited by 159
Somatostatin receptors and somatostatin content in medullary thyroid carcinomas.
Reubi, J. C., Chayvialle, J. A., Franc, B., Cohen, R., Calmettes, C., & Modigliani, E. (1991) · PubMed · Cited by 129
Self-citationTherapeutic potential for GIP receptor agonists and antagonists
Irwin, N., & Flatt, P. R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.001 · Cited by 114
Glucagon and Glucagon-Like Peptide Receptors as Drug Targets
Estall, J. L., & Drucker, D. J. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206776873671 · Cited by 96
Reubi, J. C., & Waser, B. (1996) · International Journal of Cancer · Cited by 93
Self-citationPoint Mutation of the RetProto-oncogene in the TT Human Medullary Thyroid Carcinoma Cell Line
Carlomagno, F., Salvatore, D., Santoro, M., Defranciscis, V., Quadro, L., Panariello, L., Colantuoni, V., & Fusco, A. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1287 · Cited by 78
Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances
Asmar, M., & Holst, J. J. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283339051 · Cited by 65
Taspoglutide, an Analog of Human Glucagon-Like Peptide-1 with Enhanced Stability and in Vivo Potency
Sebokova, E., Christ, A. D., Wang, H., Sewing, S., Dong, J. Z., Taylor, J., Cawthorne, M. A., & Culler, M. D. (2010) · Endocrinology · doi:10.1210/en.2009-1459 · Cited by 51
Naturally occurring medullary thyroid carcinoma in the rat.
Boorman, G. A., van Noord, M. J., & Hollander, C. G. (1972) · PubMed · Cited by 51
Incretin-Based Therapy of Type 2 Diabetes Mellitus
Knop, F. K., Vilsbøll, T., & Holst, J. J. (2009) · Current Protein and Peptide Science · doi:10.2174/138920309787315158 · Cited by 49
Ouazzani, L., Reubi, J., Volle, G., Lausson, S., Pidoux, E., Moukhtar, M. S., & Treilhou‐Lahille, F. (1994) · European Journal of Endocrinology · doi:10.1530/eje.0.1310522 · Cited by 11
Self-citationMassart, C., Gibassier, J., Raoul, M., Denais, A., Maugendre, S., Darcel, F., & Lucas, C. (1996) · Anti-Cancer Drugs · doi:10.1097/00001813-199605000-00013 · Cited by 5
Research works printed but not linked: 1
- 10.1002%2F%28SICI%291097-0215%2819960904%2967%3A5%3C644%3A%3AAID-IJC9%3E3.0.CO%3B2-U · doi:10.1002/(sici)1097-0215(19960904)67:5<644::aid-ijc9>3.0.co;2-u
Cited by
Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L. (2023) · Diabetes Care · doi:10.2337/dc22-1148 · Cited by 320
Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?
Klil-Drori, A. J., Azoulay, L., & Pollak, M. N. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.120 · Cited by 210
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Nauck, M. A. (2013) · Diabetes Care · doi:10.2337/dc12-2504 · Cited by 205
Metadata
- Authors
- Waser, B., Beetschen, K., Pellegata, N. S., & Reubi, J. C.
- Affiliations
- University of Bern (CH)
- Helmholtz Munich (DE)
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2011
- Volume
- 94
- Issue
- 4
- Pages
- 291-301
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W2078709678
- Cited by
- 80
- References
- 20
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 3 · 2019: 2 · 2018: 1 · 2017: 5 · 2016: 5 · 2015: 7 · 2014: 9 · 2013: 9 · 2012: 7
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Neuroendocrinology (publishedVersion)
- PubMed (publishedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
- Site cant be reached (submittedVersion)
- Open Access CRIS of the University of Bern
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- incretin receptors, GLP-1 receptor, GIP receptor, medullary thyroid carcinoma, C cells, C-cell hyperplasia, TT cells, type 2 diabetes treatment, species differences, receptor density, thyroid function monitoring
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Cells, Cultured, Diabetes Mellitus, Type 2, Humans, Mice, Inbred BALB C, Mice, Inbred C57BL, Receptors, Gastrointestinal Hormone, Thyroid Gland, Thyroid Neoplasms, Tumor Cells, Cultured, Rats, Sprague-Dawley, Rats, Wistar, Receptors, Glucagon, Carcinoma, Neuroendocrine, Mice, Rats, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.